JP2024511853A - Ｇｄｆ１５シグナル伝達の治療的阻害剤 - Google Patents

Ｇｄｆ１５シグナル伝達の治療的阻害剤 Download PDF

Info

Publication number
JP2024511853A
JP2024511853A JP2023560403A JP2023560403A JP2024511853A JP 2024511853 A JP2024511853 A JP 2024511853A JP 2023560403 A JP2023560403 A JP 2023560403A JP 2023560403 A JP2023560403 A JP 2023560403A JP 2024511853 A JP2024511853 A JP 2024511853A
Authority
JP
Japan
Prior art keywords
seq
domain
quel
antibody
gfral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511853A5 (https=
Inventor
スティーヴン・オライリー
アントニー・パトリック・コル
アイリーン・チミノ
イー－チェン・リー
フイ・リウ
アダム・カーペンター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104556.2A external-priority patent/GB202104556D0/en
Priority claimed from GBGB2107331.7A external-priority patent/GB202107331D0/en
Priority claimed from GBGB2108170.8A external-priority patent/GB202108170D0/en
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2024511853A publication Critical patent/JP2024511853A/ja
Publication of JP2024511853A5 publication Critical patent/JP2024511853A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023560403A 2021-03-31 2022-03-31 Ｇｄｆ１５シグナル伝達の治療的阻害剤 Pending JP2024511853A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2104556.2 2021-03-31
GBGB2104556.2A GB202104556D0 (en) 2021-03-31 2021-03-31 Therapeutic inhibitors of GDF15 signalling
GBGB2107331.7A GB202107331D0 (en) 2021-05-21 2021-05-21 Therapeutic inhibitors of GDF15 signalling
GB2107331.7 2021-05-21
GB2108170.8 2021-06-08
GBGB2108170.8A GB202108170D0 (en) 2021-06-08 2021-06-08 Theraputic inhibitors of GDF15 Signalling
PCT/EP2022/058669 WO2022207846A1 (en) 2021-03-31 2022-03-31 Therapeutic inhibitors of gdf15 signalling

Publications (2)

Publication Number Publication Date
JP2024511853A true JP2024511853A (ja) 2024-03-15
JP2024511853A5 JP2024511853A5 (https=) 2025-04-07

Family

ID=81580347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560403A Pending JP2024511853A (ja) 2021-03-31 2022-03-31 Ｇｄｆ１５シグナル伝達の治療的阻害剤

Country Status (11)

Country Link
US (1) US20240182585A1 (https=)
EP (1) EP4314071A1 (https=)
JP (1) JP2024511853A (https=)
KR (1) KR20230165285A (https=)
AU (1) AU2022251923A1 (https=)
BR (1) BR112023020152A2 (https=)
CA (1) CA3215737A1 (https=)
CO (1) CO2023013791A2 (https=)
IL (1) IL307382A (https=)
MX (1) MX2023011655A (https=)
WO (1) WO2022207846A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019510739A (ja) * 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
JP2019513224A (ja) * 2016-03-04 2019-05-23 エヌジーエム バイオファーマシューティカルス，インコー 体重を調節するための組成物及び方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8901129B2 (en) 2009-12-11 2014-12-02 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
RS59045B1 (sr) 2012-09-26 2019-08-30 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
RS59700B1 (sr) 2014-03-26 2020-01-31 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
CN108463246B (zh) 2015-10-02 2025-02-28 尤利乌斯·马克西米利安维尔茨堡大学 使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019510739A (ja) * 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
JP2019513224A (ja) * 2016-03-04 2019-05-23 エヌジーエム バイオファーマシューティカルス，インコー 体重を調節するための組成物及び方法

Also Published As

Publication number Publication date
US20240182585A1 (en) 2024-06-06
CA3215737A1 (en) 2022-10-06
EP4314071A1 (en) 2024-02-07
AU2022251923A1 (en) 2023-11-16
WO2022207846A1 (en) 2022-10-06
MX2023011655A (es) 2023-10-11
IL307382A (en) 2023-11-01
CO2023013791A2 (es) 2024-01-25
KR20230165285A (ko) 2023-12-05
BR112023020152A2 (pt) 2023-11-14

Similar Documents

Publication Publication Date Title
JP6654165B2 (ja) 抗ｔｉｅ２抗体およびその使用
CN103917562B (zh) 抗-ErbB3抗体及其用途
EP2459592B1 (en) High affinity human antibodies to human angiopoietin-2
JP6367233B2 (ja) 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用
CN102574923B (zh) 针对人蛋白酶激活受体-2的高亲和力人抗体
JP6302844B2 (ja) 抗ａｓｉｃ１抗体及びその使用
CN117120477A (zh) 针对密蛋白18a2和cd3的双特异性抗体及其应用
JP7688175B2 (ja) Ｒｅｔを結合するヒト抗体およびその使用方法
PT2187964E (pt) Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano
IL239674A (en) Molecules bind to the human ox40 receptor
TWI832013B (zh) 一種抗pd-l1抗原結合蛋白及其應用
WO2022207785A1 (en) Antibodies to gfral
AU2015316522A1 (en) Anti-met antibodies and compositions
JP2021507677A (ja) 抗ｔｒｋｂモノクローナル抗体および使用の方法
JP2024511853A (ja) Ｇｄｆ１５シグナル伝達の治療的阻害剤
JP2024534661A (ja) 抗ｂ７－ｈ３抗体及びその応用
HK40090927A (zh) 抗b7-h3抗体及其应用
CN117916262A (zh) Gdf15信号传导的治疗性抑制剂
AU2016203429A1 (en) Binding Molecules to the Human OX40 Receptor
BR112017005202B1 (pt) Anticorpo anti-met ou uma porção de ligação antigênica do mesmo, composição, seus métodos de produção, e uso
HK1166806B (en) High affinity human antibodies to human angiopoietin-2
BR112015003110B1 (pt) Anticorpo isolado monoclonal ou um seu fragmento de ligação a antígeno, molécula de ácido nucleico isolada, vetor de expressão, método para produzir anticorpo ou seu fragmento de ligação a antígeno, uso do anticorpo isolado ou de seu fragmento de ligação a antígeno, composição farmacêutica, e, uso da composição farmacêutica
BR122020013670B1 (pt) Molécula de ácido nucléico que codifica um anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 humano (hil-4r), vetor e método de produção de um anticorpo ou fragmento de ligação ao antígeno do mesmo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406